Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Most economists expect muted U.S. economic growth in the coming quarters, and some indicators suggest a mild U.S. recession is still a possibility. It may become difficult for investors to ...

The recent surge has been due to the tremendous growth Lilly has achieved due to its highly popular GLP-1 drugs, including ...

A Lilly USA LLC employee fired for allegedly misusing a corporate credit card failed to mount a viable claim that he was ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Learn More » For years, Eli Lilly has been generating solid growth ... so I wouldn't be overly concerned with it. Given its robust business and terrific portfolio of drugs, you're likely better ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on UnitedHealth (UNH – Research Report) and Eli ...

Corporate borrowers shrugged off fears over inflation and concerns over tariffs to print tight trades and pay for ...

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.